LIFE Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 3.70%
Insider Buying (Last 12 Months): $132,650.00
Insider Selling (Last 12 Months): $0.00
aTyr Pharma Insider Trading History Chart
This chart shows the insider buying and selling history at aTyr Pharma by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
aTyr Pharma Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 06/4/2024 10:09 PM ET
aTyr Pharma Insider Trading History
aTyr Pharma Institutional Trading History
Data available starting January 2016
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More on aTyr Pharma
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
269,400 shs
Average Volume
514,103 shs
Market Capitalization
$131.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.19
Who are the company insiders with the largest holdings of aTyr Pharma?